Novo Nordisk's diabetes and obesity drugs, Ozempic and Wegovy, are projected to exceed $65bn in sales this year.
Novo Nordisk's diabetes and obesity drugs, Ozempic and Wegovy, are projected to exceed $65 billion in sales this year, far surpassing the company's research budget over the last 30 years. Despite criticism over high prices, with Wegovy costing $1,349.02 monthly, experts believe market competition will lower costs, rather than government intervention. Novo's CEO will address pricing concerns in a Senate hearing amid rising demand for these treatments.
September 23, 2024
151 Articles